Cite
HARVARD Citation
Santoni, M. et al. (2022). Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis. Expert review of pharmacoeconomics & outcomes research. pp. 45-51. [Online].